Saudi Arabia has resumed oil loadings at the Ras Tanura terminal on the Persian Gulf after a nearly four-month halt due to ...
A shift in the way people think about and treat pancreatic cancer could be on the horizon based on positive results from the pivotal randomized phase 3 RASolute 302 trial comparing daraxonrasib to ...
It’s no secret the New England Patriots are thin at edge rusher. In fact, it’s probably one of their weakest positions on the roster right now. The issue became more apparent this week at Patriots ...
Good day, and welcome to the Tango Therapeutics conference call. [Operator Instructions] Please note, this call is being recorded. I'd now like to turn the call over to Liz Hickin, Vice President, ...
Austin Turner is a web producer at CBS News Los Angeles. An Inland Empire native, Austin earned a degree in journalism from San Jose State University in 2020. Before joining CBS News in 2025, he ...
An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients ...
Primary contests will be held in six states on Tuesday. We’ll be paying close attention to California, where dozens of candidates are vying to replace Gov. Gavin Newsom in an open primary. Here’s what ...
Gov. Gavin Newsom cannot run again because of term limits. The leading Democrats trying to succeed him are Xavier Becerra, a former California attorney general; and Tom Steyer, a former hedge fund ...
The Times’ results pages reveal how Californians voted for governor, U.S. House seats and in local city, school board and ballot measure races. Every registered voter in the state receives a ballot by ...
WASHINGTON (AP) — Two candidates for California governor will emerge from a massive field of 61 hopefuls in a state primary on Tuesday, when voters will also select U.S. House nominees using a new map ...
Source: Aya Gold & Silver Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program - - 30 mg onvansertib + ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results